Title: Atrial fibrillation
Content:  Rates of AF are lower in populations of African descent than in populations of European descent. The African descent is associated with a protective effect of AF, due to the low presence of SNPs with guanine alleles, in comparison with the European ancestry. European ancestry has more frequent mutations. The variant rs4611994 for the gene PITX2 is associated with the risk of AF in African and European populations. Other studies reveal that Hispanic and Asian populations have a lower risk of AF compared to populations of European descent. Also, they demonstrate that the risk of AF in non-European populations is associated with characteristic risk factors of these populations, such as hypertension.
Title: Hypertensive heart disease
Content:  Studies in the USA indicate that a disproportionate number of African Americans have hypertension compared with non-Hispanic whites and Mexican Americans, and that they suffer a greater burden of hypertensive heart disease. Heart failure is more common in people of African American ethnicity, mortality from heart failure is also consistently higher than in white patients, and it develops at an earlier age. Worryingly, recent data suggests that rates of hypertension are increasing more rapidly in African Americans than other ethnic groups. The excess of high blood pressure and its consequences in African Americans is likely to contribute to their shorter life expectancy compared with white Americans.
Title: Chronic kidney disease
Content:  African, Hispanics, and South Asians, particularly those from Pakistan, Sri Lanka, Bangladesh, and India, are at high risk of developing CKD. Africans are at greater risk due to the number of people affected with hypertension among them. As an example, 37% of ESKD cases in African Americans can be attributed to high blood pressure, compared with 19% among Caucasians. Treatment efficacy also differs between racial groups. Administration of antihypertensive drugs generally halts disease progression in white populations but has little effect in slowing kidney disease among black people, and additional treatment such as bicarbonate therapy is often required. While lower socioeconomic status contributes to the number of people affected with CKD, differences in the number of people affected by CKD are still evident between Africans and Whites when controlling for environmental factors.
Title: Pharmacogenomics
Content:  Some alleles that vary in frequency between specific populations have been shown to be associated with differential responses to specific drugs. The beta blocker atenolol is an anti-hypertensive medication that is shown to more significantly lower the blood pressure of Caucasian patients than African American patients in the United States. This observation suggests that Caucasian and African American populations have different alleles governing oleic acid biochemistry, which react differentially with atenolol. Similarly, hypersensitivity to the antiretroviral drug abacavir is strongly associated with a single-nucleotide polymorphism that varies in frequency between populations. The FDA approval of the drug BiDil (isosorbide dinitrate/hydralazine) with a label specifying African-Americans with congestive heart failure, produced a storm of controversy over race-based medicine and fears of genetic stereotyping, even though the label for BiDil did not specify any genetic variants but was based on racial self-identification.
Title: Apolipoprotein L1
Content:  1 risk allele, 4.25% with 2 risk alleles and a 50% chance of developing HIVAN for untreated HIV infected individuals. People with these allelic variants who develop ESKD begin dialysis at an earlier age than ESKD patients without the risk alleles. On average, those with two risk alleles begin dialysis approximately 10 years earlier than ESKD patients without the risk variants. The mean ages of initiation of dialysis of African American ESKD patients with two risk alleles, one risk allele, or no risk alleles are approximately 48yrs, 53yrs, and 58 yrs, respectively. Compared to African American ESKD patients, Hispanic ESKD patients with two APOL1 risk variants start dialysis at an earlier age, 41 yrs. Although, the 
Title: Essential hypertension
Content: Having a personal family history of hypertension increases the likelihood that an individual develops it. ; Essential hypertension is four times more common in black than white people, accelerates more rapidly and is often more severe with higher mortality in black patients.  More than 50 genes have been examined in association studies with hypertension, and the number is constantly growing. One of these genes is the angiotensinogen (AGT) gene, studied extensively by Kim et al. They showed that increasing the number of AGT increases the blood pressure and hence this may cause hypertension. In single variant tests, it has been shown that SNPs were enriched for variants associated with adiposity, type 2 diabetes, coronary heart disease and kidney function in previously published GWAS, providing evidence that genetic loci related to blood 
Title: Expanded criteria donor
Content:  Expanded Criteria Donor (ECD) is normally associated with kidney donors. They are also referred to as donors with "medical complexities". ECD donors are normally aged 60 years or older, or over 50 years with at least two of the following conditions: hypertension history, serum creatinine > 1.5 mg/dl or cause of death from cerebrovascular accident. Of the 9319 living kidney donations reported in the American Organ Procurement and Transplantation Network (OPTN) / United Network for Organ Sharing (UNOS) database from July 2004 to December 2005, 368 (4.0%) donors were over the age of 60 (of which 86 [0.9%] were over the age of 65), 956 (10.3%) had hypertension, 2785 (29.9%) had an eGFR < 80 mL/min per 1.73 m2 (of which 392 [4.2%] had an eGFR < 60 mL/min per 1.73 m2) and 1194 (12.8%) had a BMI > 30 kg/m2 (of which 250 [2.7%] had a BMI > 35 kg/m2) The concept of ECD was raised to address the discrepancy between demand and supply in kidney transplantation.
Title: African Society of Human Genetics
Content:  The African Society of Human Genetics (AfSHG) is a learned society and professional membership organization focused on the study of human genetics and genomics in Africans, and open to researchers who are interested in the subject. It has played a role in founding several national genetics societies, and is affiliated with the societies of Cameroon, the Democratic Republic of the Congo, Mali, Egypt, Rwanda, Senegal, South Africa, and Tanzania. As the origin of Homo sapiens, Africa is home to the widest array of human genetic diversity. The continent also has a high disease burden. Despite these factors, genetic research on the continent was inadequate, and no existing organization was sufficiently dedicated to the task. Holding its inaugural conference in Accra, Ghana, the Society was founded in 2003 to increase research capacity in Africa, support African researchers, and improve research of African people. Since then, it and its flagship project (H3Africa) have been important factors in the growth of genomic research in Africa.
Title: Apolipoprotein L1
Content:  consequently, also have a high prevalence of APOL1 risk alleles as well as APOL1 associated kidney diseases. The frequency of the risk alleles in African Americans is more than 30%. The existence of these alleles has been shown to increase the risk of developing diseases such as Focal Segmental Glomerulosclerosis(FSGS), Hypertension Attributed-End Stage Kidney Disease (ESKD), and HIV-Associated Nephropathy(HIVAN). The prevalence of the risk alleles in African Americans with these kidney diseases shown in recent studies are 67% in HIVAN, 66% in FSGS, and 47% in hypertension-attributed ESKD. Hispanic populations such as Dominicans and Puerto Ricans demonstrate a mixture of genetic influences that include African ancestry resulting in a prevalence of the APOL1 variants as well. Studies have also determined the prevalence of each individual allele in FSGS cases as well.
Title: Apolipoprotein L1
Content:  The prevalence of the G1 risk allele in African Americans with FSGS is 52% and 18-23% in those without FSGS. The prevalence of the G2 risk allele in African Americans with FSGS is 23% and 15% in those without FSGS. FSGS is a kidney disease that affects younger individuals therefore, its effects are slightly different from the effects of general non-diabetic ESKD. In a recent study, the mean ages of onset of FSGS for African Americans with 2, 1, and 0 APOL1 risk alleles was 32yrs, 36yrs and 39yrs, respectively. APOL1 variants also have a tendency to manifest FSGS at relatively young ages; FSGS begins between the ages of 15 to 39 in 70% of individuals with two APOL1 risk alleles and 42% of individuals with of 0 or 1 risk alleles.

Question: what does egfr african american mean on a blood test?
Answer: Protein.